Skripsi
STUDI IN SILICO PENELURUSAN AGEN TERAPI DIABETES MELITUS BERBASIS EKSTRAK DAUN KARAMUNTING (RHODOMYRTUS TOMENTOSA (AITON) HASSK.)
The number of diabetes mellitus cases continues to increase each year. Antidiabetic drugs are essential for individuals with diabetes, particularly type 2, to control blood glucose levels. However, commonly used modern antidiabetic drugs are often associated with adverse side effects. Therefore, natural products such as karamunting leaves (Rhodomyrtus tomentosa (Aiton) Hassk.) have been investigated as safer alternatives. This study aims to explore the bioactive compounds in karamunting leaves as potential antidiabetic agents using a network pharmacology and molecular docking approach. This approach allows for the prediction of interactions between bioactive compounds and potential target proteins. Phytochemical compounds were identified using LC-HRMS. Drug-likeness properties were evaluated using SwissADME and Molsoft, while toxicity was predicted using pkCSM. Target proteins were predicted using SwissTargetPrediction and GeneCards. Protein-protein interaction (PPI) and compound-protein interaction (CPI) analyses were conducted using Cytoscape, STRING, and STITCH. Molecular docking simulations were performed using Chimera and AutoDock Vina. The network pharmacology analysis identified three key target proteins: AKT1, PPARγ, and TNF, along with four potential bioactive compounds: mevalonate, morin hydrate, nojirimycin tetrazole, and taxifolin. The molecular docking analysis revealed that morin hydrate exhibited the strongest binding affinity toward the PPARγ receptor, with a value of −8.2 kcal/mol, which is stronger than that of metformin (−4.8 kcal/mol). The interactions involved hydrogen bonding and hydrophobic interactions with amino acid residues at the receptor’s active site. The results of this study indicate that karamunting leaf extract has potential as an antidiabetic therapeutic agent. Keywords: karamunting leaves, diabetes mellitus, in silico, molecular docking, network pharmacology